Ocugen, Inc.

NASDAQ:OCGN

Biotechnology

Healthcare
$0.74 +2.46%

+$0.03 today

Market cap
$250.82M
Beta
2.21
P/E (TTM)
-5.6
EPS (TTM)
-$0.22
52W Low $0.90High $2.73

Volume 5.83M

Average 7.51M

OCGN Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Ocugen, Inc.NASDAQ: OCGN

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables outflow grows to $0

Q1 FY2026 accounts payables was $0, compared with $0 a year earlier. Trailing-twelve-month accounts payables was $0.

Context

  • Accounts payables amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Accounts payables increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts payables holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Accounts Payables vs competitors

How OCGN compares with its peers on the latest reported figures

  • OCGN's LTM Mar 2026 accounts payables of $0 is the smallest of the 10 companies compared; the peer median is $671K.
  • Accounts payables amounts to 0.0% of revenue for OCGN, versus a peer median of 13.0%.
OCGN Competitors Peer median
Accounts Payables for OCGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$15.43M -795.9%—22.2%
ADCTADC Therapeutics S.A.LTM Mar 2026$10.3M -925.0%—13.0%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$4M +845.6%——
ALMSAlumis Inc. Common StockLTM Jun 2026$2.18M +391.0%—29.5%
NGNENeurogene Inc.LTM Mar 2026$1.34M -9.3%——
OMEROmeros CorporationLTM Mar 2026$979K -84.6%—9.9%
FULCFulcrum Therapeutics, Inc.LTM Mar 2026$943K +140.1%——
CMPXCompass Therapeutics, Inc.LTM Mar 2026$671K -192.8%——
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$665K +135.3%—4.5%
OCGNOcugen, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding OCGN) $671K-9.3%—13.0%

Competitors are the stored peer set for OCGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(58.37M)(86.8M)(63.08M)(54.05M)(67.85M)
Depreciation & Amortization229K480K704K1.97M2.39M
Deferred Income Tax(52K)0000
Stock-Based Compensation6.96M10.54M9.22M7.43M7.71M
Change in Working Capital2.49M9.2M(13.16M)3.67M(523K)
Accounts Receivables00000
Inventory00000
Accounts Payables3.5M0000
Other Working Capital(1.01M)9.2M(13.16M)3.67M(523K)
Other Non-Cash Items799K6.51M4.26M(1.15M)1.31M
Operating Cash Flow(47.94M)(60.08M)(62.05M)(42.14M)(56.96M)
Capital Expenditures(939K)(4.46M)(10.48M)(3.39M)(185K)
Acquisitions (Net)00000
Purchases of Investments0(13.27M)(3.95M)00
Sales of Investments0017.5M00
Other Investing Activities(877K)761K00(126K)
Investing Cash Flow(1.82M)(16.97M)3.08M(3.39M)(311K)
Debt Repayment(10K)500K500K30M(1M)
Common Stock Issued129.21M59.57M20.8M38.56M18.33M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(8.53M)(592K)(68K)(3.7M)0
Financing Cash Flow120.68M59.48M20.88M64.86M17.33M
Effect of Forex Changes(325)25K(5K)28K13K
Net Change in Cash70.92M(17.55M)(38.1M)19.36M(39.93M)
Free Cash Flow(48.88M)(64.54M)(72.53M)(45.53M)(57.15M)

Ocugen, Inc.

NASDAQ:OCGN

Intrinsic Alpha fair value

Locked

Current Price

$0.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.